High-throughput autoantibody profiling of different stages of Schistosomiasis japonica

References

• [cited 2023 Mar 25]. Available from: https://www.healthdata.org/results/gbd_summaries/2019/schistosomiasis-level-3-cause.
   Google Scholar
• McManus DP, Dunne DW, Sacko M, et al. Schistosomiasis. Nat Rev Dis Primers. 2018;4(1):1.
   PubMedGoogle Scholar
• Mutapi F, Maizels R, Fenwick A, et al. Human schistosomiasis in the post mass drug administration era. Lancet Infect Dis. 2017;17(2):e42–7.
   PubMed Web of Science ®Google Scholar
• Li G, Huang S, Lian L, et al. Derivation and external validation of a model to predict 2-year mortality risk of patients with advanced schistosomiasis after discharge. EBioMedicine. 2019;47:309–318.
   PubMed Web of Science ®Google Scholar
• Song L, Wu X, Ren J, et al. Assessment of the effect of treatment and assistance program on advanced patients with schistosomiasis japonica in China from 2009 to 2014. Parasitol Res. 2016;115(11):4267–4273.
   PubMed Web of Science ®Google Scholar
• Burke ML, Jones MK, Gobert GN, et al. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 2009;31(4):163–176.
   PubMed Web of Science ®Google Scholar
• Olveda DU, Inobaya M, Olveda RM, et al. Diagnosing schistosomiasis-induced liver morbidity: implications for global control. Int J Infect Dis. 2017;54:138–144.
   PubMed Web of Science ®Google Scholar
• Colley DG, Secor WE. Immunology of human schistosomiasis. Parasite Immunol. 2014;36(8):347–357.
   PubMed Web of Science ®Google Scholar
• Fu CL, Odegaard JI, Herbert DR, et al. A novel mouse model of Schistosoma haematobium egg-induced immunopathology. PLoS Pathog. 2012;8(3):e1002605.
   PubMed Web of Science ®Google Scholar
• Masi B, Perles-Barbacaru TA, Bernard M, et al. Clinical and preclinical imaging of hepatosplenic schistosomiasis. Trends Parasitol. 2020;36(2):206–226.
   PubMed Web of Science ®Google Scholar
• Wang X, Fu Q, Song R, et al. Antinuclear antibodies and interleukin responses in patients with schistosoma japonicum infection. Parasite Immunol. 2018;40(10):e12577.
   PubMed Web of Science ®Google Scholar
• Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol. 2008;4(9):491–498.
   PubMedGoogle Scholar
• Prüss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21(12):798–813.
   PubMed Web of Science ®Google Scholar
• Pereira LM, McFarlane BM, Massarolo P, et al. Specific liver autoreactivity in schistosomiasis mansoni. Trans R Soc Trop Med Hyg. 1997;91(3):310–314.
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Yan M, et al. Autoantigen microarray for high-throughput autoantibody profiling in systemic lupus erythematosus. Genom Proteom Bioinform. 2015;13(4):210–218.
   PubMed Web of Science ®Google Scholar
• Burberry A, Suzuki N, Wang JY, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8(347):347ra93.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun X, Yang W, et al. An autoimmune disease variant of IgG1 modulates B cell activation and differentiation. Science. 2018;362(6415):700–705.
   PubMed Web of Science ®Google Scholar
• Abbas MM, Kader SA. A study of autoimmunity in schistosomiasis. J Egypt Soc Parasitol. 1993;23(1):289–296.
   PubMedGoogle Scholar
• Kurata M. Schistosomiasis japonica and "autoimmunity" experimental studies. Kurume Med J. 1965;12(1):7–9.
   PubMedGoogle Scholar
• Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35(3):347–369.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369–395.
   PubMed Web of Science ®Google Scholar
• Berlin T, Zandman-Goddard G, Blank M, et al. Autoantibodies in nonautoimmune individuals during infections. Ann NY Acad Sci. 2007;1108:584–593.
   PubMed Web of Science ®Google Scholar
• Rahima D, Tarrab-Hazdai R, Blank M, et al. Anti-nuclear antibodies associated with schistosomiasis and anti-schistosomal antibodies associated with SLE. Autoimmunity. 1994;17(2):127–141.
   PubMed Web of Science ®Google Scholar
• Harboe M. Rheumatoid factors in leprosy and parasitic diseases. Scand J Rheumatol Suppl. 1988;75:309–313.
   PubMedGoogle Scholar
• Amo L, Kole HK, Scott B, et al. CCL17-producing cDC2s are essential in end-stage lupus nephritis and averted by a parasitic infection. J Clin Invest. 2021;131(11):e148000.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiong DH, Li Y, et al. Schistosoma japonicum infection in Treg-Specific USP21 knockout mice. J Immunol Res. 2021;2021:6613162.
   PubMed Web of Science ®Google Scholar
• Foster MH. Basement membranes and autoimmune diseases. Matrix Biol. 2017;57–58:149–168.
   PubMed Web of Science ®Google Scholar
• Mullazehi M, Mathsson L, Lampa J, et al. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis. 2007;66(4):537–541.
   PubMed Web of Science ®Google Scholar
• He C, Mao T, Feng Y, et al. Anti-CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus. Lupus. 2015;24(13):1370–1376.
   PubMed Web of Science ®Google Scholar